Oxford BioDynamics (OBD) AI Stock Analysis

• Market Cap: £10.08M
• Dividend Yield: N/A
• Average Volume (3M): 21.87M
• Price to Earnings (P/E): ―
• Beta (1Y): -0.66
• Revenue Growth: 72.17%
• EPS Growth: 79.03%
• Country: UK
• Employees: 51
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): >-0.01
• Shares Outstanding: 4,290,911,000
• 10 Day Avg. Volume: 50,883,470
• 30 Day Avg. Volume: 21,870,725
• PEG Ratio: <0.01
• Price to Book (P/B): 5.90
• Price to Sales (P/S): 6.02
• P/FCF Ratio: -0.85
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 38 Underperform
• Price Target: 0.23p ▼(-5.83% Downside)

Oxford BioDynamics faces significant financial and technical challenges, with persistent losses, high leverage, and bearish market momentum. The negative P/E ratio and lack of dividend yield further impact the stock's valuation. The overall score reflects these substantial risks, with financial performance being the most critical factor.

Positive Factors

Revenue Growth

The 22.21% revenue growth rate indicates strong demand for Oxford BioDynamics' offerings, suggesting potential for future profitability if operational efficiencies improve.

EpiSwitch Platform

The proprietary EpiSwitch platform positions Oxford BioDynamics as a leader in epigenetic biomarker discovery, offering a competitive edge in precision medicine.

Partnerships and Collaborations

Strategic partnerships enhance research capabilities and create additional revenue opportunities, supporting long-term growth and innovation.

Negative Factors

High Leverage

High leverage can strain financial flexibility and increase risk, potentially impacting Oxford BioDynamics' ability to invest in growth opportunities.

Negative Profitability

Ongoing losses and negative margins highlight challenges in cost management, which could hinder sustainable growth and investor confidence.

Cash Flow Challenges

Negative cash flow growth indicates liquidity issues, limiting Oxford BioDynamics' ability to fund operations and invest in strategic initiatives.

Oxford BioDynamics Business Overview & Revenue Model

Company Description

Oxford BioDynamics (OBD) is a biotechnology company specializing in precision medicine and biomarker discovery. The company operates primarily in the healthcare sector, focusing on developing and commercializing innovative diagnostic tests based on its proprietary EpiSwitch platform, which assesses epigenetic biomarkers. OBD aims to enhance patient stratification and treatment outcomes in various diseases, including cancer and autoimmune disorders, by providing accurate, reliable, and actionable insights for clinicians and researchers.

How the Company Makes Money

Oxford BioDynamics generates revenue through a combination of biomarker discovery services, partnerships with pharmaceutical and biotechnology companies, and the commercialization of its proprietary EpiSwitch technology. Key revenue streams include contract research services, which provide clients with tailored biomarker analysis and support for drug development; licensing agreements for its EpiSwitch platform, enabling partners to utilize its technology in their own research and diagnostic products; and potential royalties from any commercialized tests developed in collaboration with strategic partners. The company has established collaborations with various academic institutions and industry players, which not only enhance its research capabilities but also create additional revenue opportunities through joint ventures and shared intellectual property.

Oxford BioDynamics Financial Statement Overview

Summary

Oxford BioDynamics is facing significant financial challenges, with persistent losses and high leverage. Despite a revenue growth rate of 22.21%, profitability and cash flow remain critical concerns. The company needs to improve operational efficiency and manage debt levels to enhance financial stability.

Income Statement

Oxford BioDynamics shows a consistent pattern of negative profitability with a net profit margin of -10.19% in the latest year. Despite a revenue growth rate of 22.21%, the company struggles with negative gross and EBIT margins, indicating challenges in managing costs and achieving operational efficiency.

Balance Sheet

The company's balance sheet reveals high leverage with a debt-to-equity ratio of 4.58, indicating significant reliance on debt financing. The return on equity is negative, reflecting ongoing losses and potential risks to equity holders. The equity ratio is low, suggesting limited asset backing by equity.

Cash Flow

Cash flow analysis shows a negative free cash flow growth rate of -33.93% and a high free cash flow to net income ratio of 1.00, indicating that cash flow is closely aligned with net losses. The operating cash flow to net income ratio is negative, highlighting cash flow challenges.

Breakdown	TTM	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	1.09M	1.09M	636.00K	510.00K	154.00K	341.00K
Gross Profit	-6.15M	-6.15M	289.00K	266.00K	116.00K	-557.00K
EBITDA	-9.80M	-9.80M	-10.27M	-9.84M	-6.16M	-6.43M
Net Income	-11.15M	-11.15M	-11.57M	-10.83M	-6.71M	-6.68M
Balance Sheet
Total Assets	8.09M	8.09M	12.11M	16.13M	11.34M	15.38M
Cash, Cash Equivalents and Short-Term Investments	1.39M	1.39M	2.83M	5.25M	999.00K	4.34M
Total Debt	5.11M	5.11M	5.74M	6.44M	6.14M	6.59M
Total Liabilities	6.97M	6.97M	7.75M	10.07M	8.76M	8.69M
Stockholders Equity	1.12M	1.12M	4.36M	6.05M	2.59M	6.68M
Cash Flow
Free Cash Flow	-7.73M	-7.73M	-10.77M	-9.01M	-6.08M	-9.01M
Operating Cash Flow	-7.71M	-7.71M	-10.17M	-8.29M	-5.18M	-5.92M
Investing Cash Flow	756.00K	756.00K	-1.49M	-691.00K	1.25M	2.83M
Financing Cash Flow	6.52M	6.52M	8.25M	13.42M	2.56M	-804.00K

Oxford BioDynamics Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 0.24
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For GB:OBD, the sentiment is Negative. The current price of 0.24 is below the 20-day moving average (MA) of 0.26, below the 50-day MA of 0.31, and below the 200-day MA of 0.41, indicating a bearish trend. The MACD of -0.02 indicates Negative momentum. The RSI at 32.06 is Neutral, neither overbought nor oversold. The STOCH value of 33.33 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for GB:OBD.

Oxford BioDynamics Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
IXI	58 Neutral	£10.89M	-6.32	-15.57%	―	13.32%	55.07%
AREC	56 Neutral	£30.39M	-3.64	-204.29%	―	3.31%	21.91%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
FAB	44 Neutral	£15.91M	-9.72	-164.37%	―	-11.43%	23.40%
APTA	44 Neutral	£20.23M	-5.36	-213.66%	―	39.88%	81.33%
OBD	38 Underperform	£10.08M	-0.25	-407.49%	―	72.17%	79.03%

Oxford BioDynamics Corporate Events

Oxford BioDynamics’ Study on Predictive Cancer Test: Market Implications

Oxford BioDynamics is conducting a study titled A Prospective Real World Evidence Study (PROWES) for Concordance Rate of Blood-based 3D Genome Conformation Mapping (Episwitch CiRT®) to Identify Likelihood of Response and Actual Response Rates to PD-(L)-1 Checkpoint Inhibitors Across Multiple Oncological Indications. The study aims to assess the effectiveness of the Episwitch CiRT® test in predicting cancer patients’ responses to PD-(L)-1 checkpoint inhibitors, a type of immunotherapy.

Oxford BioDynamics Launches £7 Million Fundraising Initiative

Oxford BioDynamics has announced a fundraising initiative to raise £7 million through a placing and subscription of new ordinary shares. This funding is crucial for the company to support its operations and pursue additional business development opportunities. The funds will help the company continue its growth in PSE test sales, further develop its EpiSwitch KnowledgeBase in partnership with Google Cloud, and engage in third-party partnerships and collaborations. The fundraising is contingent on shareholder approval at a general meeting, and failure to secure this funding could necessitate alternative financial arrangements or a potential sale of the business.

The most recent analyst rating on (GB:OBD) stock is a Hold with a £0.50 price target. To see the full list of analyst forecasts on Oxford BioDynamics stock, see the GB:OBD Stock Forecast page.

Oxford BioDynamics’ EpiSwitch PSE Recognized in Prostate Cancer Screening Report

Oxford BioDynamics has been highlighted in a new report by Prostate Cancer Research, which supports the feasibility of a targeted prostate cancer screening program in the UK. The report recommends the inclusion of emerging technologies like OBD’s EpiSwitch PSE blood test in the NHS, citing its potential to significantly reduce false positives and unnecessary diagnostic procedures. The EpiSwitch PSE test, with its high specificity, could decrease the demand for MRI and biopsy procedures, thereby saving costs for the NHS and making large-scale screening more practical.

The most recent analyst rating on (GB:OBD) stock is a Hold with a £0.50 price target. To see the full list of analyst forecasts on Oxford BioDynamics stock, see the GB:OBD Stock Forecast page.

Oxford BioDynamics Unveils Breakthrough Blood Test for Chronic Fatigue Syndrome

Oxford BioDynamics has developed a groundbreaking blood test for diagnosing Chronic Fatigue Syndrome (CFS) with a high accuracy of 96%, offering a reliable diagnostic tool for a condition that affects millions globally and has long been misunderstood. This advancement, achieved using the company’s EpiSwitch® 3D genomics platform, not only promises to improve diagnosis and management of CFS but also paves the way for similar tests for conditions like long Covid, enhancing Oxford BioDynamics’ positioning in the precision diagnostics industry.

The most recent analyst rating on (GB:OBD) stock is a Hold with a £0.50 price target. To see the full list of analyst forecasts on Oxford BioDynamics stock, see the GB:OBD Stock Forecast page.

Oxford BioDynamics’ EpiSwitch CiRT Test Shows Promise in Clinical Treatment Decisions

Oxford BioDynamics has announced interim results from its PROWES trial, showcasing the clinical utility of its EpiSwitch CiRT test in guiding treatment decisions for patients undergoing immune checkpoint inhibitor therapy. The study, published in the journal Cancers, demonstrated that the CiRT test influenced treatment choices in 61% of cases, helping oncologists make more informed decisions. The test’s ability to predict patient responses with high sensitivity and specificity could lead to significant cost savings by avoiding ineffective treatments. The company plans to apply for inclusion in the US National Comprehensive Cancer Network clinical guidelines, aiming for broader adoption and commercial success.

The most recent analyst rating on (GB:OBD) stock is a Hold with a £0.50 price target. To see the full list of analyst forecasts on Oxford BioDynamics stock, see the GB:OBD Stock Forecast page.

Oxford BioDynamics Partners with Google Cloud to Advance Genomic Analytics

Oxford BioDynamics has announced a collaboration with Google Cloud to enhance its cloud-based analytical frameworks for precision medicine. This partnership will allow OBD to scale its EpiSwitch® platform using Google Cloud’s infrastructure, facilitating high-throughput, AI-powered 3D genomic analytics. The collaboration is expected to improve OBD’s digital transformation, enabling faster insights and broader access for its pharmaceutical and biotech partners, while also creating opportunities for future commercialization of its platform.